MiNK Therapeutics, Inc. (INKT)
(Delayed Data from NSDQ)
$0.69 USD
+0.01 (2.10%)
Updated Oct 14, 2024 02:08 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for MiNK Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -22.46 | -27.99 | -30.21 | -16.24 | -23.80 |
Depreciation/Amortization & Depletion | 0.20 | 0.12 | 0.08 | 0.06 | 0.04 |
Net Change from Assets/Liabilities | 2.90 | 8.77 | 3.74 | 1.48 | 7.55 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.59 | 0.24 | 13.57 | 6.37 | 1.27 |
Net Cash From Operating Activities | -15.76 | -18.87 | -12.83 | -8.34 | -14.94 |
Property & Equipment | -0.07 | -0.25 | -0.25 | -0.10 | -0.43 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.07 | -0.25 | -0.25 | -0.10 | -0.43 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -0.41 | -0.16 | 39.80 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 9.46 | 11.11 | 11.44 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -0.41 | -0.16 | 49.26 | 11.11 | 11.44 |
Effect of Exchange Rate Changes | -0.03 | 0.02 | 0.02 | -0.28 | -0.12 |
Net Change In Cash & Equivalents | -16.27 | -19.25 | 36.20 | 2.39 | -4.06 |
Cash at Beginning of Period | 19.64 | 38.89 | 2.69 | 0.30 | 4.36 |
Cash at End of Period | 3.37 | 19.64 | 38.89 | 2.69 | 0.30 |
Diluted Net EPS | -0.65 | -0.83 | -1.16 | -0.67 | NA |
Fiscal Year End for MiNK Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -6.52 | -3.81 | -22.46 | -17.00 |
Depreciation/Amortization & Depletion | NA | 0.10 | 0.05 | 0.20 | 0.15 |
Net Change from Assets/Liabilities | NA | 0.54 | 0.62 | 2.90 | 1.63 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 1.04 | 0.60 | 3.59 | 2.49 |
Net Cash From Operating Activities | NA | -4.83 | -2.54 | -15.76 | -12.73 |
Property & Equipment | NA | 0.00 | 0.00 | -0.07 | -0.07 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.00 | 0.00 | -0.07 | -0.07 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 5.81 | 0.01 | -0.41 | -0.41 |
Issuance (Repayment) of Debt | NA | 5.00 | 5.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 10.81 | 5.01 | -0.41 | -0.41 |
Effect of Exchange Rate Changes | NA | -0.03 | -0.01 | -0.03 | -0.03 |
Net Change In Cash & Equivalents | NA | 5.95 | 2.45 | -16.27 | -13.24 |
Cash at Beginning of Period | NA | 3.37 | 3.37 | 19.64 | 19.64 |
Cash at End of Period | NA | 9.31 | 5.82 | 3.37 | 6.40 |
Diluted Net EPS | NA | -0.07 | -0.11 | -0.15 | -0.15 |